Michael Okunewitch

Stock Analyst at Maxim Group

(0)
# 4989
Out of 5,291 analysts
24
Total ratings
10.53%
Success rate
-34.53%
Average return
19 Stocks
Name Action Price Target Current % Upside Ratings Updated
Chemomab Therapeutic...
Maintains: Strong Buy
4 7
1.13 519.47% 2 Feb 20, 2025
Mainz Biomed
Initiates Coverage On: Buy
14
3.59 289.97% 1 Feb 14, 2025
Lineage Cell Therape...
Maintains: Buy
5 3
0.49 512.24% 1 Jan 10, 2025
Citius Oncology
Initiates Coverage On: Buy
3
0.65 361.54% 1 Nov 27, 2024
Ocugen
Initiates Coverage On: Buy
4
0.8 400% 1 Oct 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
12
0.97 1137.11% 1 Sep 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
15 6
1.6 275% 2 Aug 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
3 12
1.71 601.75% 2 Mar 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
2
n/a n/a 1 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
24
2.22 981.08% 1 Oct 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.36 341.18% 1 Sep 21, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
108 18
3.12 476.92% 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
225
1.06 21126.42% 1 Apr 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
15.98 56.45% 1 Dec 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.82 229.67% 1 Sep 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
4
0.31 1190.32% 1 Mar 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
120
n/a n/a 1 Feb 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
1.47 1600.68% 1 Nov 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
100
1.59 6189.31% 1 Nov 30, 2021